Lack of formation of aldehyde oxidase dimer possibly due to 377G>A nucleotide substitution

Drug Metabolism and Disposition

Volumn 35, Issue 10, 2007, Pages 1860-1864

  Itoh, Kunio ^a   Maruyama, Hiroaki ^a   Adachi, Mayuko ^a   Hoshino, Kouichi ^a   Watanabe, Nobuaki ^b   Tanaka, Yorihisa ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE OXIDASE; DIMER; GENOMIC DNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; GEL PERMEATION CHROMATOGRAPHY; LIVER CYTOSOL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; SEQUENCE ANALYSIS; SPECIES DIFFERENCE; STATISTICAL ANALYSIS; STRAIN DIFFERENCE; WESTERN BLOTTING;

ALDEHYDE OXIDASE; ANIMALS; BASE SEQUENCE; CYTOSOL; DIMERIZATION; LIVER; MALE; NUCLEOTIDES; POLYMORPHISM, GENETIC; RATS; RATS, INBRED STRAINS; SEQUENCE ANALYSIS, DNA; SPECIES SPECIFICITY;

RATTUS;

EID: 34748924472     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.015503     Document Type: Article

References (26)

1. Beedham C (1985) Molybdenum hydroxylases as drug-metabolizing enzymes. Drug Metab Rev 16:119-156.
2. Beedham C (1987) Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. Prog Med Chem 24:85-121.
3. Beedham C (1997) The role of non-P450 enzymes in drug oxidation. Pharm World Sci 19:255-263.
4. Beedham C (1998) Molybdenum hydroxylases, in Metabolism of Xenobiotics (Gorrod JW, Oeschlager H, and Caldwell J eds) pp 51-58. Taylor & Francis, London.
5. Beedham C (2002) Molybdenum hydroxylase, in Enzyme Systems That Metabolise Drug and Other Xenobiotics (Ioannides C, ed) pp 147-187. John Wiley, Chichester, UK.
6. Beedham C, Miceli JJ, and Obach S (2003) Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharm 23:229-232.
7. Gluecksohn-Waelsch S, Greengard P, Quinn GP, and Teicher LS (1967) Genetic variations of an oxidase in mammals. J Biol Chem 242:1271-1273.
8. Hoshino K, Itoh K, Masubuchi A, Adachi M, Asakawa T, Watanabe N, Kosaka T, and Tanaka Y (2007) Cloning, expression, and characterization of male cynomolgus monkey liver aldehyde oxidase. Biol Pharm Bull 30:1191-1198.
9. Itoh K, Maruyama H, Adachi M, Hoshino K, Watanabe N, and Tanaka Y (2007a) Lack of dimer formation ability in rat strains with low aldehyde oxidase activity. Xenobiotica 37:709-716.
10. Itoh K, Masubuchi A, Sasaki T, Adachi M, Watanabe N, Nagata K, Yamazoe Y, Hiratsuka M, Mizugaki M, and Tanaka Y (2007b) Polymorphism of aldehyde oxidase in Donryu rats. Drug Metab Dispos 35:734-739.
11. Itoh K, Yamamura M, Muramatsu S, Hoshino K, Masubuchi A, Sasaki T, and Tanaka Y (2005) Stereospecific oxidation of (S)-enantiomer of RS-8359, a selective and reversible MAO-A inhibitor, by aldehyde oxidase. Xenobiotica 35:561-573.
12. Itoh K, Yamamura M, Takasaki W, Sasaki T, Masubuchi A, and Tanaka Y (2006) Species differences in enantioselective 2-oxidation of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidase. Biopharm Drug Dispos 27:1133-1139.
13. Jordan CGM, Rashidi MR, Laljee H, Clarke SE, Brown JE, and Beedham C (1999) Aldehyde oxidase-catalyzed oxidation of methotrexate in the liver of guinea pig, rabbit and man. J Pharm Pharmacol 51:411-418.
14. Kitamura S, Nakatani K, Sugihara K, and Ohta S (1999a) Strain differences of the ability to hydroxylate methotrexate in rats. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 122:331-336.
15. Kitamura S, Sugihara K, Nakatani K, Ohta S, O'Hara T, Nimomiya S, Green CE, and Tyson CA (1999b) Variation of hepatic methotrexate 7-hydroxylase activity in animals and humans. IUBMB Life 48:607-611.
16. Kitamura S, Sugihara K, and Ohta S (2006) Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83-98.
17. Miura H, Naoi M, Nakahara D, Ohta T, and Nagatsu T (1993) Changes in monoamine levels in mouse brain elicited by forced-swimming stress, and the protective effect of a new monoamine oxidase inhibitor, RS-8359. J Neural Transm 94:175-187.
18. Plenker A, Puchler K, and Volz HP (1997) The effects of RS-8359 on cardiovascular function in healthy subjects and depressed patients. Int Clin Psychopharmacol 12 (Suppl 5):S25-S29.
19. Prakash C, Kamel A, Gummerus J, and Wilner K (1997) Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab Dispos 25:863-875.
20. Puchler K, Schaffler K, and Plenker A (1997) The comparative effects of single and multiple doses of RS-8359, moclobemide and placebo on psychomotor function in healthy subjects. Int Clin Psychopharmacol 12 (Suppl 5):S17-S23.
21. Rashidi MR, Smith JA, Clarke SE, and Beedham C (1997) In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit and rat liver. Drug Metab Dispos 25:805-813.
22. Sasaki T, Masubuchi A, Yamamura M, Watanabe N, Hiratsuka M, Mizugaki M, Itoh K, and Tanaka Y (2006) Rat strain differences in stereospecific 2-oxidation of RS-8359, a reversible and selective MAO-A inhibitor, by aldehyde oxidase. Biopharm Drug Dispos 27:247-255.
23. Sugihara K, Kitamura S, and Tatsumi K (1995) Strain differences of liver aldehyde oxidase in rats. Biochem Mol Biol Int 37:861-869.
24. Takasaki W, Yamamura M, Nozaki A, Nitanai T, Sasahara K, Itoh K, and Tanaka Y (2005) Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent drug metabolizing enzymes. Chirality 17:135-141.
25. Wright RM, Clayton DA, Riley MG, McManaman JL, and Repine JE (1999) cDNA cloning, sequencing, and characterization of male and female rat liver aldehyde oxidase (rAOX1). J Biol Chem 274:3878-3886.
26. Yokoyama T, Karube T, and Iwata N (1989) Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in vitro and in vivo in mouse brain. J Pharm Pharmacol 41:32-36.